×

Stocks Boston Scientific Corp

  • boston_scientific.jpg

    Sales of drug-coated stents, Boston Scientific's most profitable products, came in at the low end of the company's guidance in the fourth quarter. Stents are the fragile little wire mesh cylinders that act like scaffolding to prop open clogged arteries.

  • Stocks opened lower Tuesday after an unexpectedly sharp contraction in the U.S. services sector and a fresh downgrade in the financial sector.

  • graphic_word_ofthe_street.jpg

    Stocks lost ground Monday, coming off their best week in nearly five years. What's the word on the Street?

  • Boston Scientific Corp.

    Boston Scientific on Monday posted a fourth quarter net loss as it took charges related to restructuring operations, divesting assets and patent litigation.

  • Stocks closed higher as investors appeared more enthused about Microsoft's bid for Yahoo! than they were concerned about the latest signs of economic weakness. The three major indexes each gained about 3-4 percent for the week, but the market still has a way to go to recover from January's rout.

  • Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Abbott Laboratories moved closer to joining the U.S. market for drug-coated heart stents on Thursday as an advisory panel backed the company's experimental device.

  • Medical device maker Boston Scientific said on Monday it agreed to sell its cardiac surgery and vascular surgery businesses to Sweden's Getinge Group for $750 million.

  • Even as much of the economy contracts, health care continues to grow, and investment opportunities continue to grow with it. What to choose among those investment opportunities? Analyst Michael Magiera of Manning & Napier looks past some of the more volatile pharmaceutical stocks.

  • gsk_logo.jpg

    Shares in the world's second biggest drug company, GlaxoSmithKline, are giving back all of yesterday's gains in early trading this morning. That's because sales of its embattled diabetes drug, Avandia and other Avandia-related products took a huge dive in the third quarter. Down 48% in the U.S. from the same time last year.

  • Boston Scientific Corp.

    Boston Scientific posted a third-quarter net loss on Friday, hit by hefty acquisition and divestiture charges.

  • Boston Scientific said on Wednesday it would cut about 2,300 jobs as part of its effort to reduce operating expenses.

  • johnson_johnson2_logo.jpg

    If you saw the headline, you would've thought that Johnson and Johnson might help power the Dow today. The hybrid pharmaceutical, medical device and consumer healthcare products company handily beat the Street and raised its guidance for the year.

  • Medical device maker Boston Scientific is preparing to slash thousands of jobs to counter slumping sales, according to a media report Tuesday.

  • stent_AP.jpg

    Late yesterday an FDA panel of outside experts unanimously recommended the agency approve Medtronic's drug-coated stent called, "Endeavor". Unlike drugs, there is no telegraphed date for an agency decision, but analysts think the FDA will approve the device by the end of the year or early next year.

  • BREAKING: Reuters reports FDA panel backs drug-coated stents made by Medtronic (MDT).

  • U.S. health regulators charged Boston Scientific with inadequate record-keeping and reporting following the deaths of five patients implanted with an experimental device to treat a dangerous ballooning of the body's main artery.

  • Medical device maker Medtronic, feeling the pinch of a slowdown in one of its key markets, will eliminate about 900 jobs through early retirement packages, voluntary and involuntary separations, the company said in a filing.

  • Patients given drug-coated stents after an acute heart attack are nearly five times more likely to die six months to two years later than those with bare metal forms of the arterial scaffolding, research showed on Tuesday.

  • A U.S. court dismissed some claims in a lawsuit filed by Johnson & Johnson over its failed bid for Guidant.